CFX News and Press, Colfax Corporation From 02/21/20

Colfax Corporation (CFX) Q4 2019 Results Conference Call February 21, 2020 08:00 AM ET Company Participants Mike Macek - Vice President of Finance, Investor Relations Matt Trerotola - President and Chief Executive Officer Chris Hix - Senior Vice President and Finance & Chief...

Image source: The Motley Fool. Colfax Corp   (NYSE: CFX) Q4 2019 Earnings Call Feb 21, 2020 , 8:00 a.m. ET Operator Continue reading

Colfax ( CFX +4.7% ) reported Q4 net sales growth of 54.5% Y/Y to $888.37M, due to the acquisition of DJO; and on organic basis sales increased by 1.7%. More news on: Colfax Corporation, Stocks on the move, Earnings news and commentary, Read more ...

Colfax (NYSE: CFX ): Q4 Non-GAAP EPS of $0.61 beats by $0.05 ; GAAP EPS of $0.24 beats by $0.01 . More news on: Colfax Corporation, Earnings news and commentary, Read more ...

•         Reported $0.24 EPS from continuing operations and achieved $0.61 of adjusted EPS •         Delivered 7.5% year-on-year sales growth in Medical Technology segment including 7.8% organic improvement •...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb’s 13F stock portfolio on a quarterly basis. It is based on Third Point’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Dan Loeb’s Third Point Portfoli...

Annapolis Junction, MD, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter of 2019 on the morning of Friday, February 21, 2020. The ...

Zimmer Biomet ( ZBH ) (“Zimmer”) has certainly had some issues since the acquisition of Biomet. Between integration challenges, manufacturing problems (including FDA warning letters), and slow underlying market growth, and other challenges to boot, the shares have dramatically ...

Credit where due - not only has Colfax ( CFX ) management reduced the cyclicality of the business in a relatively short time, it has also added a credible acyclical healthcare platform and improved the execution of its ESAB welding business. That progress has translated into strong outperforma...

This article is part of a series that provides an ongoing analysis of the changes made to Wallace Weitz’s 13F portfolio on a quarterly basis. It is based on Weitz’s regulatory 13F Form filed on 11/13/2019. Please visit our Tracking Wallace Weitz’s Weitz Investment Manag...